Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study
Clinical Lymphoma Myeloma and Leukemia · 2024
DOI: 10.1016/j.clml.2024.02.008 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024. Verfasst von Xiaoshuai Zhang und 45 weiteren Autor:innen. Beteiligte Einrichtung: Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Ke…. Hauptthemen laut MEDLINE: Dasatinib, Imatinib Mesylate. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: Foundation for Innovative Research Groups of the National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND: There are limited data comprehensively comparing therapy responses and outcomes among nilotinib, dasatinib, flumatinib and imatinib for newly diagnosed chronic-phase chronic myeloid leukemia in a real-world setting. PATIENTS AND METHODS: Data from patients with chronic-phase CML receiving initial a second-generation tyrosine-kinase inhibitor (2G-TKI, nilotinib, dasatinib or flumatinib) or imatinib therapy from 77 Chinese centers were retrospectively interrogated. Propensity-score matching (PSM) analyses were performed to to compare therapy responses and outcomes among these 4 TKIs. RESULTS: 2,496 patients receiving initial nilotinib (n = 512), dasatinib (n = 134), flumatinib (n = 411) or imatinib (n = 1,439) therapy were retrospectively interrogated in this study. PSM analyses indicated that patients receiving initial nilotinib, dasatinib or flumatinib therapy had comparable cytogenetic and molecular responses (p = .28-.91) and survival outcomes including failure-free survival (FFS, p = .28-.43), progression-free survival (PFS, p = .19-.93) and overall survival (OS) (p values = .76-.78) but had significantly higher cumulative incidences of cytogenetic and molecular responses (all p values < .001) and higher probabilities of FFS (p < .001-.01) than those receiving imatinib therapy, despite comparable PFS (p = .18-.89) and OS (p = .23-.30). CONCLUSION: Nilotinib, dasatinib and flumatinib had comparable efficacy, and significantly higher therapy responses and higher FFS rates than imatinib in newly diagnosed CML patients. However, there were no significant differences in PFS and OS among these 4 TKIs. These real-world data may provide additional evidence for routine clinical assessments to identify more appropriate therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, Chin…
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Sichuan, China.
- Department of Hematology, The First Hospital of Jilin University, Jilin, China.
- National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China.
- Department of Hematology, The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Förderung
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China
Zitieren
APA
Zhang, X., Xu, N., Yang, Y., Lin, H., Liu, B., Du, X., Liu, X., Liang, R., Chen, C., Huang, J., Zhu, H., Pan, L., Wang, X., Li, G., Liu, Z., Zhang, Y., Liu, Z., Hu, J., Liu, C., …, & Jiang, Q. (2024). Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.02.008
Vancouver
Zhang X, Xu N, Yang Y, Lin H, Liu B, Du X, et al. Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study. Clinical Lymphoma Myeloma and Leukemia. 2024. doi:10.1016/j.clml.2024.02.008
BibTeX
@article{Zhang2024,
author = {Zhang, Xiaoshuai and Xu, Na and Yang, Yunfan and Lin, Hai and Liu, Bingcheng and Du, Xin and Liu, Xiaoli and Liang, Rong and Chen, Chunyan and Huang, Jian and Zhu, Huanling and Pan, Ling and Wang, Xiaodong and Li, Guohui and Liu, Zhuogang and Zhang, Yanqing and Liu, Zhenfang and Hu, Jianda and Liu, Chunshui and Li, Fei and Yang, Wei and Meng, Li and Han, Yanqiu and Lin, Li'e and Zhao, Zhenyu and Tu, Chuanqing and Zheng, Caifeng and Bai, Yanliang and Zhou, Zeping and Chen, Suning and Qiu, Huiying and Yang, Lijie and Sun, Xiuli and Sun, Hui and Zhou, Li and Liu, Zelin and Wang, Danyu and Guo, Jianxin and Pang, Liping and Zeng, Qingshu and Suo, Xiaohui and Zhang, Weihua and Zheng, Yuanjun and Zhang, Yanli and Li, Weiming and Jiang, Qian},
title = {Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
doi = {10.1016/j.clml.2024.02.008}
}
EUVIMED